psychrights.org - /Drugs/DolinvGSKTrial/Exhibits/
[To Parent Directory]
4/27/2017 9:04 AM 102657 2-Forst-Pltfs-Add-Facts-Preemption_Redacted.pdf
7/3/2018 2:07 PM <dir> _vti_cnf
4/27/2017 9:04 AM 656860 Dolin-Pltf-Statement-of-Fact-Preemption-gsk-redactions-003.pdf
4/27/2017 9:12 AM 19963331 DX-101-Letter-from-GSK-dated-March-8-2006-Re-New-Drug-Application-for-Paxil.pdf
4/27/2017 9:12 AM 2417124 DX-123-Email-dated-May-2-2007-from-Renmeet-Grewal-at-the-FDA-to-Barbara-Arning-at-GSK-re-Adult-Suicidality-Letter.pdf
4/27/2017 9:12 AM 678885 DX-124-Email-dated-May-7-2007-from-Renmeet-Grewal-at-the-FDA-to-Barbara-Arning-at-GSK-re-Paxil-labeling.pdf
4/27/2017 9:12 AM 2254396 DX-128-Email-dated-June-21-2007-from-Renmeet-Grewal-at-the-FDA-about-class-labeling-revisions-for-all-drugs-to-treat-major-depressive-disorder.pdf
4/27/2017 9:12 AM 186657 DX-129-Email-dated-June-22-2007-from-Renmeet-Grewal-at-the-FDA-re-class-labeling-revisions.pdf
4/27/2017 9:11 AM 4398704 DX-25-Letter-from-GSK-dated-December-16-1999-General-Correspondence-Response-to-FDA-Request-for-Information.pdf
4/27/2017 9:12 AM 395233 DX127-Email-dated-May-15-2007-from-Renmeet-Grewal-at-the-FDA-to-Barbara-Arning-at-GSK-re-Paxil-specific-language-labeling.pdf
4/27/2017 9:04 AM 273395 GSKtimeline1-edited.pdf
4/27/2017 9:04 AM 147109 GSKtimeline2.pdf
4/27/2017 9:08 AM 11504129 JX-1-Paxil-label-prescribing-information-with-black-box-label-showing-no-risk-beyond-age-24.pdf
4/27/2017 9:18 AM 18188946 JX-13-Clinical-Review-Relationship-Between-Antidepressant-Drugs-and-Suicidality-in-Adults.pdf
4/27/2017 9:13 AM 9611193 JX-2-2008-Mylan-Pharmaceuticals-Inc-paroxetine-label-prescribing-information.pdf
4/27/2017 9:06 AM 6934219 JX-4-GSK-to-healthcare-professionals-Dear-Doctor-letter-re-Clinical-Worsening-and-Suicide-Risk.pdf
4/27/2017 9:14 AM 11382099 JX-5-Paxil-Tablet-and-Oral-Suspension-Prescribing-Information-re-Suicidality-in-Children-and-Adolescents.pdf
4/27/2017 9:14 AM 8742736 JX-6-February-2005-Letter-from-GSK-to-Healthcare-Professionals-re-Boxed-Warning-has-been-added-to-Paxil.pdf
4/27/2017 9:16 AM 15600417 JX-7-May-2004-Letter-from-GSK-to-Healthcare-Professionals-re-the-FDA-cautioning-physicians-to-closely-monitor-people-being-treated-with-antidepressants.pdf
4/27/2017 9:16 AM 9381931 JX-8-2004-Paxil-Tablet-and-Oral-Suspension-Description-and-Prescribing-Information.pdf
4/27/2017 9:09 AM 73677 PTX-008-GSK-Email-to-FDA-from-Arning-re-GSK-Paroxetine-Adult-Suicidality-Analysis-MDD-and-non-MDD-5-Apr-06.pdf
4/27/2017 9:09 AM 2426991 PTX-009-Apr-5-2006-GSK-letter-to-FDA-w-briefing-doc-and-proposed-labeling.pdf
4/27/2017 9:06 AM 62065 PTX-012-Stone-Jones-excerpts.pdf
4/27/2017 9:09 AM 656206 PTX-013-Paroxetine-Clinical-Worsening-And-Suicide-Risks-In-Adults-revised-by-Dr-Kraus-10-Apr-06.pdf
4/27/2017 9:10 AM 348108 PTX-014-Teicher-1990.pdf
4/27/2017 9:10 AM 34608 PTX-016-GSK-internal-email-dated-6252001.pdf
4/27/2017 9:06 AM 60309 PTX-017-Email-from-Burnham-to-Kumar-regarding-FDA-request-for-the-incidence-of-all-deaths-and-suicides-18-Nov-99.pdf
4/27/2017 9:10 AM 106212 PTX-026-SKB-Memo-from-Brand-to-SKF-re-Approved-Clinicals-Papers-for-Field-Consultant-Use-25-Apr-95.pdf
4/27/2017 9:10 AM 244457 PTX-027-FDA-email-between-Mosholder-and-Katz-regarding-Paxil-and-Pediatric-Suicidality-3-Jun-03.pdf
4/27/2017 9:10 AM 612817 PTX-028-Paxil-Summary-Basis-of-Approval.pdf
4/27/2017 9:10 AM 2101291 PTX-030-Life-Expectancy-Charts-22-Sep-15.pdf
4/27/2017 9:06 AM 395212 PTX-034-Dunner-Dunbar.pdf
4/27/2017 9:10 AM 558702 PTX-048-1992-Paxil-Label.pdf
4/27/2017 9:05 AM 1794602 PTX-075-Integrated-Summary-of-Safety-1989-excerpt (1).pdf
4/27/2017 9:05 AM 1794602 PTX-075-Integrated-Summary-of-Safety-1989-excerpt.pdf
4/27/2017 9:10 AM 1171920 PTX-082-SKB-letter-from-Donnelly-to-Leber-FDA-re-paroxetine-Suicidal-Ideation-Behavior-10-May-91.pdf
4/27/2017 9:06 AM 121195 PTX-100-Memo-Brand-re-Metanalaysis-Examining-Suicidal-Ideation-5-Jul-95.pdf
4/27/2017 9:11 AM 54241 PTX-110-Email-from-Kohler-to-Kline-SKB-regarding-FDA-request-for-data-on-deaths-24-Jun-99.pdf
4/27/2017 9:11 AM 82545 PTX-114-Email-Brand-to-Kumar-re-Incidence-of-death-suicide-in-Paroxetine-7-Dec-99.pdf
4/27/2017 9:11 AM 111875 PTX-115-SKB-memo-and-record-of-FDA-convo-with-Seika-re-FDA-request-for-deaths-and-suicides-8-Dec-99.pdf
4/27/2017 9:11 AM 453274 PTX-122-Results-for-review-about-suicide-attempts-in-1991-report-by-Davies-6-Feb-02.pdf
4/27/2017 9:11 AM 81420 PTX-124-Wheadon-memo-to-reanalyze-NDA-data-on-Suicide-Attempts-with-Paxil-10-Apr-02.pdf
4/27/2017 9:05 AM 371319 PTX-129-Results-for-review-about-suicides-in-1991-report-by-Davies-10-May-02.pdf
4/27/2017 9:11 AM 1726250 PTX-293-Paxil-Label-PDR-2002.pdf
4/27/2017 9:11 AM 1193407 PTX-344-GSK-Monthly-Highlights-for-June-2007.pdf
4/27/2017 9:04 AM 66222 Should-Have-Happened.pdf
4/27/2017 9:04 AM 137060 StewartDolinPaxil_print96x40.pdf